Loading
Cancer, Lipids, and Metabolism / Cancer, Stress, Anesthesia, and Immune Response · Journal article
Exploration of Drug Science · August 17, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review summarizing the repositioning of non-oncology drugs for cancer combination therapy. It outlines mechanisms, screening approaches, and challenges but does not present original empirical results or quantified clinical outcomes to support efficacy claims.
Journal article.
Review synthesizes synergistic potential of metformin, statins, antimalarials, antipsychotics, NSAIDs, β-blockers, antihistamines, and cardiovascular drugs in cancer combination therapy. Mechanisms discussed include targeting tumor microenvironment, metabolic reprogramming, and epigenetic regulation alongside standard or targeted therapies.
No original efficacy or safety data reported; review does not quantify synergistic effects with numeric outcomes.
This review provides a conceptual framework for drug repositioning strategies but does not furnish evidence-based recommendations for clinical practice. Clinicians should view this as a synthesis of mechanisms and rationale requiring validation by controlled trials before implementation.
This is a narrative review article that synthesizes existing evidence on drug repositioning concepts and mechanisms rather than reporting original empirical findings or clinical outcomes from a controlled study.
This review provides a conceptual framework for drug repositioning strategies but does not furnish evidence-based recommendations for clinical practice. Clinicians should view this as a synthesis of mechanisms and rationale requiring validation by controlled trials before implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Cancer treatment faces severe challenges such as drug resistance, side effects, and high costs. The “repurposing old drugs” strategy, which involves repositioning approved drugs for non-oncology indications for cancer treatment, has opened up new avenues for developing efficient, low-toxicity, and rapidly translatable combination therapies. This strategy can not only accelerate clinical translation by leveraging known pharmacological and safety data but also generate synergistic effects with standard chemotherapy, targeted therapy, or immunotherapy by targeting non-classical pathways such as the tumor microenvironment, metabolic reprogramming, and epigenetic regulation. This paper aims to systematically review the repositioning strategies of non-oncology drugs in cancer combination therapies, focusing on their mechanisms of action, synergistic principles, high-throughput screening and computational prediction methods, as well as pre-clinical and clinical research progress based on models such as patient-derived organoids. The paper systematically analyzes the synergistic effects and potential of representative drugs such as metformin, statins, antimalarials, antipsychotics, non-steroidal anti-inflammatory drugs, β-blockers, antihistamines, and cardiovascular drugs. It also summarizes the current challenges in drug screening, mechanism validation, commercial incentives, clinical trial design, and safety re-evaluation, aiming to provide a theoretical basis and future research directions for optimizing cancer combination treatment strategies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.